Cargando…

Exploratory Study of Superparamagnetic Iron Oxide Dose Optimization in Breast Cancer Sentinel Lymph Node Identification Using a Handheld Magnetic Probe and Iron Quantitation

SIMPLE SUMMARY: Sentinel lymph node biopsy (SLNB) using super magnetic iron oxide (SPIO) and magnetic probes is expected to be a simple and safe method of detecting cancerous lymph nodes without using radioisotopes (RIs). A multicenter trial of SLNB was conducted using a handheld magnetic probe and...

Descripción completa

Detalles Bibliográficos
Autores principales: Taruno, Kanae, Kuwahata, Akihiko, Sekino, Masaki, Nakagawa, Takayuki, Kurita, Tomoko, Enokido, Katsutoshi, Nakamura, Seigo, Takei, Hiroyuki, Kusakabe, Moriaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946828/
https://www.ncbi.nlm.nih.gov/pubmed/35326561
http://dx.doi.org/10.3390/cancers14061409
_version_ 1784674284406308864
author Taruno, Kanae
Kuwahata, Akihiko
Sekino, Masaki
Nakagawa, Takayuki
Kurita, Tomoko
Enokido, Katsutoshi
Nakamura, Seigo
Takei, Hiroyuki
Kusakabe, Moriaki
author_facet Taruno, Kanae
Kuwahata, Akihiko
Sekino, Masaki
Nakagawa, Takayuki
Kurita, Tomoko
Enokido, Katsutoshi
Nakamura, Seigo
Takei, Hiroyuki
Kusakabe, Moriaki
author_sort Taruno, Kanae
collection PubMed
description SIMPLE SUMMARY: Sentinel lymph node biopsy (SLNB) using super magnetic iron oxide (SPIO) and magnetic probes is expected to be a simple and safe method of detecting cancerous lymph nodes without using radioisotopes (RIs). A multicenter trial of SLNB was conducted using a handheld magnetic probe and SPIO (Rizobist(®)) and its non-inferiority with the conventional RI method. The quantity of iron in SLN was measured to examine the necessary dosage and administration method for sufficient SLN detection in the case of this test. Further, a clinical trial was conducted to determine the possibility of SLNB with a half-dose of SPIO (1.0 mL → 0.5 mL), and the resulting iron volume measured at that time was also examined. This study demonstrates that sufficient iron content reaches SLN even at an SPIO dose of 0.5 mL. ABSTRACT: This exploratory study compared doses of ferucarbotran, a superparamagnetic iron oxide nanoparticle, in sentinel lymph nodes (SLNs) and quantified the SLN iron load by dose and localization. Eighteen females aged ≥20 years scheduled for an SLN biopsy with node-negative breast cancer were divided into two equal groups and administered either 1 mL or 0.5 mL ferucarbotran. Iron content was evaluated with a handheld magnetometer and quantification device. The average iron content was 42.8 µg (range, 1.3–95.0; 0.15% of the injected dose) and 21.9 µg (1.1–71.0; 0.16%) in the 1-mL and 0.5-mL groups, respectively (p = 0.131). The iron content of the closest SLN compared to the second SLN was 53.0 vs. 10.0 µg (19% of the injected dose) and 34.8 vs. 4.1 µg (11.1%) for the 1-mL and 0.5-mL groups, respectively (p = 0.001 for both). The magnetic field was high in both groups (average 7.30 µT and 6.00 µT in the 1-mL and 0.5-mL groups, respectively) but was not statistically significant (p = 0.918). The magnetic field and iron content were correlated (overall SLNs, p = 0.02; 1-mL, p = 0.014; 0.5-mL, p = 0.010). A 0.5-mL dose was sufficient for SLN identification. Primary and secondary SLNs could be differentiated based on iron content. Handheld magnetometers could be used to assess the SLN iron content.
format Online
Article
Text
id pubmed-8946828
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89468282022-03-25 Exploratory Study of Superparamagnetic Iron Oxide Dose Optimization in Breast Cancer Sentinel Lymph Node Identification Using a Handheld Magnetic Probe and Iron Quantitation Taruno, Kanae Kuwahata, Akihiko Sekino, Masaki Nakagawa, Takayuki Kurita, Tomoko Enokido, Katsutoshi Nakamura, Seigo Takei, Hiroyuki Kusakabe, Moriaki Cancers (Basel) Article SIMPLE SUMMARY: Sentinel lymph node biopsy (SLNB) using super magnetic iron oxide (SPIO) and magnetic probes is expected to be a simple and safe method of detecting cancerous lymph nodes without using radioisotopes (RIs). A multicenter trial of SLNB was conducted using a handheld magnetic probe and SPIO (Rizobist(®)) and its non-inferiority with the conventional RI method. The quantity of iron in SLN was measured to examine the necessary dosage and administration method for sufficient SLN detection in the case of this test. Further, a clinical trial was conducted to determine the possibility of SLNB with a half-dose of SPIO (1.0 mL → 0.5 mL), and the resulting iron volume measured at that time was also examined. This study demonstrates that sufficient iron content reaches SLN even at an SPIO dose of 0.5 mL. ABSTRACT: This exploratory study compared doses of ferucarbotran, a superparamagnetic iron oxide nanoparticle, in sentinel lymph nodes (SLNs) and quantified the SLN iron load by dose and localization. Eighteen females aged ≥20 years scheduled for an SLN biopsy with node-negative breast cancer were divided into two equal groups and administered either 1 mL or 0.5 mL ferucarbotran. Iron content was evaluated with a handheld magnetometer and quantification device. The average iron content was 42.8 µg (range, 1.3–95.0; 0.15% of the injected dose) and 21.9 µg (1.1–71.0; 0.16%) in the 1-mL and 0.5-mL groups, respectively (p = 0.131). The iron content of the closest SLN compared to the second SLN was 53.0 vs. 10.0 µg (19% of the injected dose) and 34.8 vs. 4.1 µg (11.1%) for the 1-mL and 0.5-mL groups, respectively (p = 0.001 for both). The magnetic field was high in both groups (average 7.30 µT and 6.00 µT in the 1-mL and 0.5-mL groups, respectively) but was not statistically significant (p = 0.918). The magnetic field and iron content were correlated (overall SLNs, p = 0.02; 1-mL, p = 0.014; 0.5-mL, p = 0.010). A 0.5-mL dose was sufficient for SLN identification. Primary and secondary SLNs could be differentiated based on iron content. Handheld magnetometers could be used to assess the SLN iron content. MDPI 2022-03-10 /pmc/articles/PMC8946828/ /pubmed/35326561 http://dx.doi.org/10.3390/cancers14061409 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Taruno, Kanae
Kuwahata, Akihiko
Sekino, Masaki
Nakagawa, Takayuki
Kurita, Tomoko
Enokido, Katsutoshi
Nakamura, Seigo
Takei, Hiroyuki
Kusakabe, Moriaki
Exploratory Study of Superparamagnetic Iron Oxide Dose Optimization in Breast Cancer Sentinel Lymph Node Identification Using a Handheld Magnetic Probe and Iron Quantitation
title Exploratory Study of Superparamagnetic Iron Oxide Dose Optimization in Breast Cancer Sentinel Lymph Node Identification Using a Handheld Magnetic Probe and Iron Quantitation
title_full Exploratory Study of Superparamagnetic Iron Oxide Dose Optimization in Breast Cancer Sentinel Lymph Node Identification Using a Handheld Magnetic Probe and Iron Quantitation
title_fullStr Exploratory Study of Superparamagnetic Iron Oxide Dose Optimization in Breast Cancer Sentinel Lymph Node Identification Using a Handheld Magnetic Probe and Iron Quantitation
title_full_unstemmed Exploratory Study of Superparamagnetic Iron Oxide Dose Optimization in Breast Cancer Sentinel Lymph Node Identification Using a Handheld Magnetic Probe and Iron Quantitation
title_short Exploratory Study of Superparamagnetic Iron Oxide Dose Optimization in Breast Cancer Sentinel Lymph Node Identification Using a Handheld Magnetic Probe and Iron Quantitation
title_sort exploratory study of superparamagnetic iron oxide dose optimization in breast cancer sentinel lymph node identification using a handheld magnetic probe and iron quantitation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946828/
https://www.ncbi.nlm.nih.gov/pubmed/35326561
http://dx.doi.org/10.3390/cancers14061409
work_keys_str_mv AT tarunokanae exploratorystudyofsuperparamagneticironoxidedoseoptimizationinbreastcancersentinellymphnodeidentificationusingahandheldmagneticprobeandironquantitation
AT kuwahataakihiko exploratorystudyofsuperparamagneticironoxidedoseoptimizationinbreastcancersentinellymphnodeidentificationusingahandheldmagneticprobeandironquantitation
AT sekinomasaki exploratorystudyofsuperparamagneticironoxidedoseoptimizationinbreastcancersentinellymphnodeidentificationusingahandheldmagneticprobeandironquantitation
AT nakagawatakayuki exploratorystudyofsuperparamagneticironoxidedoseoptimizationinbreastcancersentinellymphnodeidentificationusingahandheldmagneticprobeandironquantitation
AT kuritatomoko exploratorystudyofsuperparamagneticironoxidedoseoptimizationinbreastcancersentinellymphnodeidentificationusingahandheldmagneticprobeandironquantitation
AT enokidokatsutoshi exploratorystudyofsuperparamagneticironoxidedoseoptimizationinbreastcancersentinellymphnodeidentificationusingahandheldmagneticprobeandironquantitation
AT nakamuraseigo exploratorystudyofsuperparamagneticironoxidedoseoptimizationinbreastcancersentinellymphnodeidentificationusingahandheldmagneticprobeandironquantitation
AT takeihiroyuki exploratorystudyofsuperparamagneticironoxidedoseoptimizationinbreastcancersentinellymphnodeidentificationusingahandheldmagneticprobeandironquantitation
AT kusakabemoriaki exploratorystudyofsuperparamagneticironoxidedoseoptimizationinbreastcancersentinellymphnodeidentificationusingahandheldmagneticprobeandironquantitation